✨ Medicine Distribution Consents




4 APRIL

NEW ZEALAND GAZETTE

839

Dosage Form:
Solution for infusion

New Zealand Sponsor:
Baxter Healthcare Limited

Manufacturer:
Clintec Parenteral S.A., Zone Industrielle d’Amilly, Montargis, France

Product:
Ritalin LA

Active Ingredient:
Methylphenidate hydrochloride 20mg

Dosage Form:
Modified release capsule

New Zealand Sponsor:
Novartis New Zealand Limited

Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America

Product:
Ritalin LA

Active Ingredient:
Methylphenidate hydrochloride 30mg

Dosage Form:
Modified release capsule

New Zealand Sponsor:
Novartis New Zealand Limited

Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America

Product:
Ritalin LA

Active Ingredient:
Methylphenidate hydrochloride 40mg

Dosage Form:
Modified release capsule

New Zealand Sponsor:
Novartis New Zealand Limited

Manufacturer:
Elan Holdings, Gainesville, Georgia, United States of America

Dated this 28th day of March 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go2244

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:

Schedule

Product:
Cancidas

Active Ingredient:
Caspofungin acetate 57.8mg equivalent to 50mg caspofungin anhydrous free base

Dosage Form:
Powder for concentrate for infusion

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America

Product:
Cancidas

Active Ingredient:
Caspofungin acetate 60.6mg equivalent to 50mg caspofungin anhydrous free base

Dosage Form:
Powder for infusion

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America

Product:
Cancidas

Active Ingredient:
Caspofungin acetate 83.9mg equivalent to 70mg caspofungin anhydrous free base

Dosage Form:
Powder for infusion

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturer:
Merck & Co Inc, West Point, Pennsylvania, United States of America

Product:
NovoMix 30 NovoLet

Active Ingredient:
Insulin aspart 100IU/mL

Dosage Form:
Suspension for injection

New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited

Manufacturer:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark

Product:
NovoMix 30 Penfill

Active Ingredient:
Insulin aspart 100IU/mL

Dosage Form:
Suspension for injection

New Zealand Sponsor:
Novo Nordisk Pharmaceuticals Limited

Manufacturer:
Novo Nordisk A/S, Bagsvaerd, Copenhagen, Denmark

Dated this 28th day of March 2002.

G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).

go2245



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2002, No 31


Gazette.govt.nz PDF NZ Gazette 2002, No 31





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicine Primene (continued from previous page)

πŸ₯ Health & Social Welfare
Medicines, Consent, Primene, Baxter Healthcare Limited
  • G. R. Boyd, Chief Advisor, Safety and Regulation

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
28 March 2002
Medicines, Consent, Cancidas, NovoMix 30
  • G. R. Boyd, Chief Advisor, Safety and Regulation